Malaria Vaccine to Cost $5

The first malaria vaccine recommended by the World Health Organization (WHO) is expected to become significantly less expensive in Africa soon.

This news is essential as most of the malaria-endemic countries have the highest rates of infections and deaths, which are found in Africa.

Bharat Biotech International Limited (BBIL) and GSK plc today announced that Bharat Biotech will reduce the price of the RTS,S vaccine (Mosquirix™) by more than half, to less than $5, progressively by 2028.

This price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. Bharat Biotech has invested over $200 million in new, higher-output manufacturing facilities, product development, and technology transfers.

Dr. Krishna Ella, Executive Chairman of BBIL, said in a press release, "Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. For us, this is more than a cooperation, it’s a promise..... At Bharat Biotech, we believe technology must deliver on three essentials: safety, affordability, and accessibility."

"With this collaboration, we are turning this belief into real impact, to ensure life-saving vaccines reach the communities that need them most.”

With Gavi’s support, 12 endemic countries in Africa will have introduced RTS,S through routine immunisation programmes by the end of 2025.

As of June 26, 2025, neither malaria vaccine is available in the United States.